INTRODUCTION
Coronary artery disease (CAD) is a highly prevalent cardiovascular (CV) pathology and is the main cause of mortality worldwide and a major burden on public health (Leal et al., 2006) . It will remain the leading cause of death for coming years (Mathers and Loncar, 2006) . CV mortality in Latvia is higher than in the European Union on average (Anonîms, 2011) . Due to aging of the population and improved prognosis of coronary patients, the number of CAD patients in the future may increase (Tunstall-Pedoe et al., 1999) . Despite recent advances in management of CAD via more effective treatment for acute coronary syndrome, revascularisation and improved prevention, CAD remains a major public health concern and improvement in outcome of the disease continues to be a challenge.
Understanding of the cardiovascular (CV) risk factors (RFs) and treatment have markedly changed over the years. During the last decade, strong evidence has supported the concept about resting heart rate (HR) as an important prognostic RF (Diaz et al., 2005; Fox et al., 2008a; Bohm et al., 2010) . Both the BEAUTIFUL and SHIFT studies in a prospective way confirmed the prognostic value of increased resting HR. BEAUTIFUL showed an association of HR ³70 beats per minute (bpm) with significantly increased CV risk in CAD patients with left ventricular dysfunction (Fox et al., 2008a) . Another prospective study, SHIFT, confirmed high HR as a RF and important target for treatment in heart failure .
Based on a large body of evidence, high resting HR as an independent CV RF is included in the European and Latvian guidelines on CV disease prevention (Çrglis u.c., 2007; Graham et al., 2007; Perk et al., 2012) .
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CONTROL OF RESTING HEART RATE AND OTHER RISK FACTORS OVER A THREE-YEAR PERIOD IN OUTPATIENTS WITH STABLE CORONARY ARTERY DISEASE IN LATVIA
Inga Balode*, Sanda Jçgere**, Iveta Bajâre***, Iveta Mintâle**, Inga Narbute**, Oskars Rasnaès****, Gustavs Latkovskis** , *****, and Andrejs Çrglis** , *** , ***** Latvia. Patients (n = 120) The aim of the study was to evaluate control of resting HF as well as other RFs over three-year period in treated outpatients with established stable CAD, by annual collection and analysis of information about RFs (including increased HR), medical history, physical examination and clinical data, as well as the treatment. Following our previous publication on baseline data of the study (Balode et al., 2011) , the current paper focuses on three-year follow-up data.
The aim of the study was to evaluate control of heart rate (HR) and other risk factors (RF) over a three-year period in coronary artery disease (CAD) outpatients in

MATERIALS AND METHODS
We surveyed 120 treated outpatients with established stable CAD. Ten cardiologists and two general practitioners working in different regions of Latvia took part in the study, by including 6 to 12 CAD patients each and observing them over a three-year period (from November 2009 to April 2013). CAD was confirmed by history of at least one inclusion criteria: documented myocardial infarction (more than three months ago), coronary stenosis more than 50% (confirmed by coronary angiography), chest pain in combination with myocardial ischemia (confirmed by stress ECG, stress echocardiography or myocardial imaging), coronary revascularisation (coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)) more than three months ago. Exclusion criteria were hospitalisation due to CV disease within the last three months, planned revascularisation and limited cooperation of a patient. A case report form for baseline data contained the following parts: demographic information, RFs and lifestyle, medical history, physical examination, current symptoms, most recent measurements (glucose level, total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, left ventricular ejection fraction (LVEF)), and current treatment. After the inclusion visit when baseline data were collected, patients were questioned and examined once per year during annual visits. During the whole follow-up period, four measurements per each parameter were collected (if available) for each patient. A case report form for annual data contained the following parts: clinical outcomes, RFs and lifestyle, physical examination, current symptoms, most recent measurements and treatment. The resting HR was estimated by two methods: pulse palpation and electrocardiography (ECG). Pulse palpation was performed after sitting for at least 5 min in a quiet room with comfortable temperature; then HR was measured for 30 seconds, two measurements were taken, and the second was recorded. For ECG the most recent ECG within six months was used. No special investigations, measurements or treatment changes took place during this observational study. Over the entire follow-up period, patients were managed in a normal manner by treating physicians.
High HR was defined as ³70 (bpm) according to recent evidence (Fox et al., 2008a) . In accordance with Latvian guidelines on CV prevention (Çrglis u.c., 2007) : total cholesterol ³5 mmol/l, LDL-C ³3 mmol/l, triglycerides ³1.7 mmol/l, glucose level ³5.6 mmol/l, body mass index (BMI) ³25 kg/m 2 , systolic blood pressure ³140 mmHg and diastolic ³90 mmHg were assessed as high; HDL-C level was defined as low at <1.2 mmol/l for women and <1 mmol/l fom men. BMI was calculated by using height and weight in kg/m 2 . Waist circumference ³80 cm for women and ³94 cm for men was defined as increased according to criteria of metabolic syndrome (Alberti et al., 2005) .
Target doses for b blockers were defined as follows: 200 mg daily (mg/d) for metoprolol, 10 mg/d for bisoprolol and nebivolol and 50 mg/d for carvedilol in accordance with the expert consensus document on b-adrenergic receptor blockers (Lopez-Sendon et al., 2004) and the newest European heart failure guidelines (McMurray et al., 2012) . The target dose for betaxolol was defined as 20 mg/d according to SPC (Summary of Product Characteristics) (Anonîms, 2013a) .
Approval of the Ethics Committee of the Research Institute of Cardiology, University of Latvia, was obtained before enrollment of patients into study. P values < 0.05 were considered as statistically significant.
Data were processed with methods of descriptive as well as analytical statistics using the Statistical Package for the Social Sciences (SPSS), version 20.0.
RESULTS
Heart rate. HR values at baseline and during the follow-up period are summarised in Table 1 . When compared, only HR values measured by palpation differed (were lower) from baseline data in Y2 (Wilcoxon test, P = 0.027). The proportion of patients with increased HR at baseline as well as during the follow-up period was about one-third (Table  2) . When comparing Y1, Y2, Y3 values with baseline data, no significant changes in the proportion of patients with increased HR were found (McNemar's test, P > 0.05).
Clinical outcomes. During the three-year period, of 120 patients participating in the study, at least one clinical outcome was documented in 45 (37.5%) patients: 5 (4.2%) patients died and 40 (33.3%) had non-fatal clinical outcome. In the majority of cases (n = 4), death was due to CV reasons, one patient died from non-CV disease. In total, 88 non-fatal CV events were documented during follow-up. The most frequent were coronary angiography, unstable angina and percutaneous coronary intervention (PCI) ( Table  3 ).
Mean baseline HR in patients with or without any clinical outcome was 66.1 ± 9.7 bpm (by pulse palpation), 65.5 ± 10.9 bpm (by ECG), 68.2 ± 8.9 bpm (by pulse palpation), and 67.4 ± 10.2 bpm (by ECG), respectively. No statistically significant differences were found between patients with or without clinical events in terms of baseline HR (independent t-test, P > 0.050 for both comparisons). Mean baseline HR by pulse palpation and ECG in patients who died during the follow-up period were 72.6 ± 16.9 bpm and 71.4 ± 17.4 bpm, respectively. However, it did not differ significantly from patients who survived (67.5 ± 9.2 bpm by pulse palpation and 66.7 ± 10.4 bpm by ECG) (independent For abbreviations see Table 1 T a b l e 3 Other measurements. Regarding the most recently recorded measurements (Table 4) LVEF at baseline, at Y1, Y2 and Y3 was 57.1 ± 8.7%, 58.0 ± 7.8%, 57.8 ± 8.4%, 56.9 ± 10.2%, respectively. It did not differ at Y1-Y3 from baseline values (paired sample ttest, P > 0.05) and the proportion of patients with decreased LVEF ((%) did not differ: 4 (4.2%) at baseline, 1 (1.9%) at Y1, 1 (1.8%) at Y2 and 3 (5.6%), P > 0.05, McNemar's test).
Current symptoms. Angina symptoms at baseline, Y1, Y2 and Y3 were present in 47.5% (n = 57), 39.0% (n = 46), 43.5% (n = 50) and 37.7% (n = 43) of patients, respectively. Significant improvement in angina symptoms was found at Y1 and Y3 vs baseline (Wilcoxon test, P = 0.001 in both cases). In patients with angina, average consumption of nitrates per month at baseline, Y1, Y2 and Y3 was 7.7 ± 5.2, 4.4 ± 3.1, 5.6 ± 3.2 and 5.1 ± 3.4, respectively. Consumption of nitrates decreased significantly at Y1, Y2, Y3 vs baseline (paired sample t-test, P = 0.001, P = 0.015, P = 0.004, respectively).
The number of patients with heart failure at baseline and at Y1, Y2, Y3 was 69 (57.5%), 69 (68.5%), 73 (63.5%) and 75 (65.8%), respectively. Significant worsening in heart failure symptoms was found atY3 vs baseline data (McNemar's test, P = 0.022).
Treatment. Treatment of patients with different classes of drugs is summarised in Table 5 .
Preventive treatment. During the follow-up period, the number of patients receiving antithrombotic agents was invariably high (Table 5 ). The proportion of patients receiving antithrombotic agents and proportion of patients using statins and angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) did not differ at Y1-Y3 vs baseline data (McNemar's test, P > 0.05 in all cases).
HR reducing agents.
Regarding heart rate reducing agents, patients were using b blockers and ivabradin (number of patients using these agents during the follow-up period are summarised in Table 5 ). No patient used digoxin or amiodaron as a single HR reducing agent without b blocker or ivabradin. Non-dihidropiridin Ca antagonists were not used at all. Among b blockers, metoprolol, bisoprolol, nebivolol and carvedilol were used. One patient at Y1 received betaxolol (10 mg/d). Most frequently, patients were receiving metoprolol and bisoprolol (Table 5) Table 6 : no differences were found at Y1, Y2 and Y3 compared to baseline data (Wilcoxon test, P > 0.050 in all cases).
The proportion of patients using ivabradin significantly increased at Y1, Y2 and Y3 in comparison with baseline data (McNemar's test, P = 0.016, P < 0.001, P < 0.001, respectively). The median ADD of ivabradin at baseline and at Y1-Y3 was 5.0 (IQR = 5.0) mg/d and 15.0 (IQR = 5.0) mg/d, respectively. Doses of ivabradin at Y2, Y2 and Y3 significantly increased vs baseline values (Wilcoxon test, P = 0.002, P = 0.002 and P = 0.001, respectively). The number of patients using ivabradin in combination with b blocker was 3 (2.5%) at baseline and 9 (7.6%), 17 (14.8%) 20 (17.5%) at Y1, Y2 and Y3, respectively. The proportion of patients using this combination significantly increased at Table 1 * < 1.2 mmol/l for women and < 1.0 mmol/l for men Y1, Y2, Y3 comparing to baseline values (McNemar's test, P = 0.031, P < 0.001, P < 0.001, respectively).
HR reducing agents in the group of patients with increased resting HR ³70 bpm. Regarding patients with increased HR (documented at least in one visit), more than 90% of patients with HR ³70 bpm, ³75 bpm, ³80 bpm and ³85 bpm were using b blocker or ivabradin. However, HR reducing agents were not used at all in 6-8% of patients with increased HR: in 5 (6.9%), 3 (6.4%), 2 (6.3%) and 2 (5.0%) cases of patients with HR ³70 bpm, ³75 bpm, ³80 bpm and ³85 bpm, respectively (when HR was documented by pulse palpation) and in 4 (6.8%), 3 (6.7%), 2 (9.7%) and 2 (8.3%) cases of patients with HR ³70 bpm, ³75 bpm, ³80
bpm and ³85 bpm, respectively (when HR was documented by ECG).
The number of patients using ivabradin, b blockers and ivabradin in combination with b blockers according to HR are summarised in Table 1 ; *documented at least in one visit; **used at least one year the proportion of patients using Ca antagonists significantly increased in comparison with baseline data (McNemar's test, P = 0.039 and P = 0.012, respectively). The proportion of patients using nitrates did not change vs baseline data (McNemar's test, P > 0.050). The number of patients using other antianginal agents (trimetazidin in all cases, except one patient at Y2 and Y3 using ranolazin) was: 15 (12.5%) at baseline 17 (14.4%) at Y1, 20 (17.4%) and 21 (18.4%) at Y3 and it increased at Y3 vs baseline (McNemar's test, P = 0.031). The proportion of patients using diuretics increased at Y1, Y2 and Y3 vs baseline (McNemar's test, P = 0.031, P = 0.004 and P < 0.001, respectively).
DISCUSSION
Observed clinical outcomes in our study are typical for CAD patients, with domination of non-fatal coronary events (coronary angiography, unstable angina, PCI). The documented fatal events were connected with progression or complications of CV disease, as in the majority of deceased patients, cause of death was CV. Our data did not show the well known relationship between increased HR and CV events (including mortality) (Diaz et al., 2005; Fox et al., 2008a) . Although HR in deceased patients was higher than in patients who survived, the difference does not reach statistical significance. This is probably connected with a low sample size of observed patients and too short follow-up period.
In our study, the proportion of patients using preventive treatment was high, indicating a favourable trend to follow guidelines and consider CV prevention by treating CAD patients. However, the high mortality rate from CV diseases in Latvia (Anonîms, 2011) indicates a need to use all possibilities by practitioners to control CV RFs when treating CAD patients.
Data from analysed sample indicates a good tendency for better control of several important RFs over the three-year period: mean number of smoked cigarettes per day in smokers decreased, systolic blood pressure as well as number and proportion of patients with increased blood pressure decreased significantly. Also, control of dyslipidemia improved, as the level of triglycerides decreased, and proportion of patients with normal HDL-C increased. This seems encouraging and shows a connection between regular control of CAD patients by practitioners and progress in management of RFs, even during the relatively short period of time. However, this is not the case with HR. In our sample the percentage of CAD patients with increased HR (³70 bpm) was lower than in the Euro Heart Survey (EHS) and REALITY Latvia (Daly et al., 2008; Balode et al., 2010) , but the proportion of patients with increased HR (³70 bpm) did not change over the three-year period. EHS analysed information from 156 cardiology clinics in 34 countries with 3031 patient included, on the basis of a new clinical diagnosis of stable angina by a cardiologist . In EHS, the proportion of patients with increased HR (³70 bpm) was 53% (Daly et al., 2008) . REALITY Latvia results are particularly interesting, as this study reflects the situation in Latvia with stable angina management four years before the start of our study. That study analysed 300 stable angina outpatients treated by cardiologists and highlighted increased HR and its management (Balode et al., 2010) . The proportion of patients with increased HR ³70 bpm in REALITY Latvia was 43%. In our study the proportion of patients with increased HR was lower (36% by pulse palpation and 34% by ECG at the beginning of study). This suggests that HR management has improved, as REALITY Latvia was performed seven years ago. However, the patients in REALITY Latvia and in our study are not the same. Examination of HR control in our study during a three-year follow-up period of the same population suggests lack of improvement in HR. The proportion of patients with increased HR was high (around one-third) and stable over the three-year period, indicating a need for better control of this RF. HR is one of the most frequently assessed clinical parameters, which can be easily followed even by patients, and should be better controlled, especially taking into account the strong association of increased HR with CV events (Fox et al., 2008a) in CAD patients.
The current study does not indicate movement of patients from the group with increased HR to the group with normal HR or vice versa, over the follow-up period. It does not answer the question if patients did not respond to treatment with HR reducing agents. That type of analysis would be very useful in further studies.
Our data indicate unused potential for better control of HR. The most commonly used agents with HR reducing effect are b blockers. The proportion of patients using b blockers was high (more than 80%), but the used doses were far from b blocker target doses. Long-term compliance and underdosing of b blockers is typical, as in real life patients are using significantly less dosages than those used in clinical trials (Gislason, 2006) . Around 50% of patients on b blockers in our study were using 2% of the target dose and our data did not show any change in doses of b blockers used over the three-year period. Use of nebivolol, a b blocker with relatively weak HR reducing effect, increased during the follow-up period. Also, in 6-8% of cases, despite increased HR, patients did not use any HR reducing agent. In our study, patients were mainly treated by cardiologists. In real life, stable CAD patients are more frequently treated by general practitioners. As understanding of increased HR as an independent CV RF and important target for treatment can be significantly lower among general practitioners, in comparison with cardiologists, HR control in patients treated by general practitioners is likely even weaker.
However, there are some positive tendencies in management of HR -practitioners are starting to use ivabradin more frequently, as well as more commonly combining b blockers with ivabradin. Ivabradin is good HR lowering agent without influence on other cardiac functions and provides antianginal and antiishemic efficacy in case of angina (Anonymous, 2013b) . There is also evidence about ability of ivabradin to reduce risk of events (Fox et al., 2008b; Fox et al., 2009; Swedberg et al., 2010) . Our data show that use of ivabradin is more frequent when HR is significantly higher than 70 bpm -at the level ³ 85 bpm. In those patients, higher doses of b blockers (³ 50 from target dose)
were less frequently used, probably due to side effects, as incidence of b blocker intolerance was higher in this group. Insufficient reduction of HR is indication for combination of b blocker with ivabradin. However, our data suggest that ivabradin is added to treatment not because of HR, but because of intolerance of b blockers. Newest European as well Latvian heart failure guidelines recommend adding ivabradin when HR is ³70 bpm (McMurray et al., 2012) . Use of higher doses of b blockers and more frequent combination with ivabradin in patients with ³70 bpm could be potentially beneficial for better control of HR in CAD patients.
Limitations for interpretation of the results should be acknowledged, as the number of patients involved was relatively small and the follow-up period was rather short. Selection bias may also have taken place. For better understanding of how management of increased HR and other RFs in stable CAD patients is changing, studies with a bigger number of patients and a longer follow-up period are needed. The results of the study indicate improvement over the three-year period in the management of several important RFs, like smoking, increased blood pressure as well dyslipidemia, in the analysed sample of treated outpatients with established CAD.
However, prevalence of patients with increased HR (³70 bpm) remained high (around one-third) and stable, indicating a need for better control.
Use of higher doses of b blockers and more frequent combination of b blockers with ivabradin in patients with HR ³70 bpm could be an unused potential for better control of increased HR and an additional step towards reduction of coronary events and improvement of symptoms in CAD patients.
